| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-08 | Immatics Biotechnologies (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-07 | Ipsen (France) Aepodia (Belgium) | collaboration |
Collaboration agreement | |||
| 2016-01-07 | Enterome Bioscience (France) INRA (France) Janssen Biotech , a J&J company (USA - NJ) | novel targets and bioactive molecules from the gut microbiome | Crohn\'s disease | R&D collaboration |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | R&D agreement |
| 2016-01-07 | C4 Therapeutics (USA - MA) Roche (Switzerland) | Degronimids - targeted protein degradation (TPD) therapeutics | collaboration R&D |
R&D agreement | ||
| 2016-01-07 | Transgene (France) | restructuring |
Cancer - Oncology | Restructuring | ||
| 2016-01-07 | Kite Pharma (USA - CA) National Cancer Institute (NCI) (USA) | anti-CD19 chimeric antigen receptor (CAR) product candidate | B-cell lymphomas and leukemias | R&D |
Cancer - Oncology | R&D agreement |
| 2016-01-07 | Scancell (UK) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-07 | Genticel (France) Roche Molecular Systems | cobas® HPV Test | collaboration |
Cancer - Oncology - Infectious diseases | Collaboration agreement | |
| 2016-01-07 | Adaptimmune (UK) | nomination |
Autoimmune diseases | Nomination | ||
| 2016-01-07 | Swedish Orphan Biovitrum - SOBI (Sweden) - PharmaSwiss (Switzerland) | Relistor®, Deflux®, Solesta® | opioid-induced constipation (OIC), vesicoureteral reflux,faecal incontinence in patients 18 years and older | distribution |
Digestive diseases - Gastrointestinal diseases - Urological diseases | Distribution agreement |
| 2016-01-07 | Janssen Sciences Ireland, a J&J company (USA - NJ) ViiV Healthcare (USA - UK) | cabotegravir and rilpivirine | maintenance treatment for VIH patients who have achieved viral suppression. | clinical research commercialisation |
Infectious diseases | Clinical research agreement |
| 2016-01-07 | Johnson & Johnson Innovation, Janssen Pharmaceuticals, a J&J company (USA - NJ) Chia Tai Tianqing Pharmaceutical Group (China) | undisclosed immune-modulating agents | hepatitis B | licensing |
Infectious diseases - Liver diseases | Licensing agreement |
| 2016-01-07 | Kymab (UK) The University of Texas MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit (USA - TX) | novel human therapeutic antibodies | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-01-07 | Aegerion Pharmaceuticals (USA - MA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-01-07 | Medivation (USA - CA) NanoString Technologie (USA - WA) | companion diagnostic test for enzalutamide | triple negative breast cancer | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2016-01-07 | Merck KGaA (Germany) Biocartis (Belgium) | liquid biopsy RAS biomarker test | metastatic colorectal cancer | development commercialisation |
Cancer - Oncology - Diagnostic | Development agreement |
| 2016-01-07 | Cellectis (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-07 | Takeda Pharmaceutical (Japan) Baxalta (USA - IL) | US biologics manufacturing facility | plant acquisition |
Plant acquisition | ||
| 2016-01-07 | Apogenix (Germany) CANbridge Life Sciences (China) | APG101 | solid tumors and malignant hematological diseases | licensing |
Cancer - Oncology | Milestone |
| 2016-01-07 | Teva Pharmaceutical Industries (Israel) Checkpoint Therapeutics (USA - NY) | CEP-8983 and CEP-9722 | development |
Cancer - Oncology | Development agreement |
